Abstract
Migraine undergoes both an evolving state in the formative years but also has a remitting state which bears resemblance to the former. Underlying genetics may contribute to the initiating sequence for these processes but the patient’s lifetime environment may influence the expression of the disease. Systems rarely thought of in terms of neurologic disease such as the inflammatory system may have significant contributions to modulating this process and accounting for the clinical presentation of migraine.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Kurth T. The association of migraine with ischemic stroke. Curr Neurol Neurosci Rep. 2010;10:133–9. Important paper looking at the factors involved in migraine related stroke.
Bartleson JD, Cutrer FM. Migraine update. Diagnosis and treatment. Minn Med. 2010;93:36–41.
Stovner LJ, Zwart JA, Hagen K, et al. Epidemiology of headache in Europe. Eur J Neurol. 2006;13:333–45.
Wang SJ. Epidemiology of migraine and other types of headache in Asia. Curr Neurol Neurosci Rep. 2003;3:104–8.
Natoli JL, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30:599–609.
Lipton RB, Hamelsky SW, Stewart WF. Epidemiology and impact of migraine. In: Silberstein SD, Lipton RB, Dalessio DJ, editors. Wolff’s Headache and Other Head Pain. New York: Oxford University Press; 2001. p. 85–107.
Victor TW, Hu X, Campbell JC, Buse DC, Lipton RB. Migraine prevalence by age and sex in the United States: a life-span study. Cephalalgia. 2010;30:1065–72.
Bigal ME, Lipton RB. Migraine at all ages. Curr Pain Headache Rep. 2006;10:207–13.
Scher AI, Bigal ME, Lipton RB. Comorbidity of migraine. Curr Opin Neurol. 2005;18:305–10.
Meyer JS, Terayama Y, Konno S, et al. Age-related cerebrovascular disease alters the symptomatic course of migraine. Cephalalgia. 1998;18:202–8.
Robertson WM, Welch KMA, Levine SL, Schultz LR. The effects of aging on cerebral blood flow in migraine. Neurology. 1989;39:947–51.
Aiba S, Tatsumoto M, Saisu A, et al. Prevalence of typical migraine aura without headache in Japanese ophthalmology clinics. Cephalalgia. 2010;30:962–7.
Kelman L. The Aura: a tertiary care study of 952 migraine patients. Cephalalgia. 2004;24:728–34.
Headache Classification Committee of the International Headache Society. The international classification of headache disorders. Cephalalgia. 2004;24:1–160.
Silberstein S, Loder E, Diamond S, et al. Probable migraine in the United States: results of the American Migraine Prevalence and Prevention (AMPP) study. Cephalalgia. 2007;27:220–9.
Feleppa M, Bigal M, Lipton R. Headache in the elderly. Neurology. 2005;61 suppl 1:133–4.
Martins K, Bigal ME, Bordini CA, Speciali JG. Migraine in the elderly. Headache. 2006;46:312–6.
••Bigal ME, Liberman JN, Lipton RB. Age-dependent prevalence and clinical features of migraine. Neurology. 2006;67:246–51. A detailed examination of how migraine changes clinically with age across the lifespan.
Wöber-Bingöl Ç, Wöber C, Karwautz A, et al. Clinical features of migraine: a cross-sectional study in patients aged three to sixty-nine. Cephalalgia. 2004;24:12–7.
Rostrup E, Gouw AA, Vrenken H, et al. The spatial distribution of age-related white matter changes as a function of vascular risk factors—Results from the LADIS study. NeuroImage. 2012;60:1597–607.
Igarashi H, Sakai F, Kan S, Okada J, Tazaki Y. Magnetic resonance imaging of the brain in patients with migraine. Cephalalgia. 1991;11:69–74.
Murray ME, Vemuri P, Preboske GM, et al. A quantitative postmortem MRI design sensitive to white matter hyperintensity differences and their relationship with underlying pathology. J Neuropathol Exp Neurol. 2012;71:1113–22.
••Turkoglu R, Tuzun E, Icor S, et al. Antineuronal antibodies in migraine patients with white matter lesions. Int Neurosci. 2011;121:33–6. First exploration of an uncharted area with significant implications.
Tisserand DJ, van Boxtel MP, Pruessner JC, et al. A voxel-based morphometric study to determine individual differences in gray matter density associated with age and cognitive change over time. Cereb Cortex. 2004;14:966–73.
Rocca MA, Ceccarelli A, Falini A, et al. Brain gray matter changen migraine patients with T2-visible lesions A 3-T MRI study. Stroke. 2006;37:1765–70.
Sarchielli P, Alberti A, Baldi A, et al. Proinflammatory cytokines, adhesion molecules, and lymphocyte integrin expression in the internal jugular blood of migraine patients without aura assessed ictally. Headache. 2006;46:200–7.
Puente J, Jaque M, Carrasco C, et al. Triptan drugs, natural killer cell cytotoxicity, and neutrophils pro-matrix metalloproteinase-9 secretion. Headache. 2008;48:1482–9.
Vanhoutte PM, Scott-Burden T. The endothelium in health and disease. Tex Hear Inst J. 1994;21:62–7.
Bartley J. Could glial activation be a factor in migraine? J Med Hypotheses. 2009;72:255–7.
Bilbo SD, Smith SH, Schwarz JM. A lifespan approach to neuroinflammatory and cognitive disorders: a critical role for Glia. J Neuroimmune Pharmacol. 2012;7:24–41.
Grinberg YY, Milton JG, Kraig RP. Spreading depression sends microglia on levy flights. PLoS One. 2011;6:e19294.
Grinberg YY, Dibbern ME, Levasseur VA, Kraig RP. Insulin-like growth factor-1 abrogates microglial oxidative stress and TNF-α responses to spreading depression. J Neurochem. 2013. doi:10.1111/jnc.12267 [Epub ahead of print].
•Brown DR. Role of microglia in age-related changes to the nervous system. Sci World J. 2009;9:1061–71. Very comprehensive examination of the work done to date on microglia.
Welch KM, Nagesh V, Aurora SK, Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache. 2001;41:629–37.
Ebersberger A, Schaible H-G, Averbeck B, Richter F. Is there a correlation between spreading depression, neurogenic inflammation, and nociception that might cause migraine headache? Ann Neurol. 2001;49:7–13.
Durham PL, Garrett FG. Neurological mechanisms of migraine: potential of the gap junction modulator tonabersat in prevention of migraine. Cephalalgia. 2009;29 Suppl 2:1–6.
Wenk GL, Pierce DJ, Struble RG, Price DL, Cork LC. Age-related changes in multiple neurotransmitter systems in the monkey brain. Neurobiol Aging. 1989;10:11–9.
Meltzer CC, Smith G, DeKosky ST, et al. Serotonin in aging, late-life depression, and alzheimer’s disease: the emerging role of functional imaging. Neuropsychopharmacology. 1988;18:407–30.
Glorioso C, Sibille E. Between destiny and disease: genetics and molecular pathways of human central nervous system aging. Prog Neurobiol. 2011;93:165–81.
Compliance with Ethics Guidelines
Conflict of Interest
Dr. Frederick G. Freitag reported receiving consultancy from Transcept and honoraria from Allergan. Dr. Freitag reported receiving payment for the development of educational presentations including service on speakers’ bureaus from Zegenix. Dr. Freitag is employed with the HealthTexas Provider Network.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is part of the Topical Collection on Migraine
Rights and permissions
About this article
Cite this article
Freitag, F.G. Why Do Migraines Often Decrease As We Age?. Curr Pain Headache Rep 17, 366 (2013). https://doi.org/10.1007/s11916-013-0366-3
Published:
DOI: https://doi.org/10.1007/s11916-013-0366-3